How Korean law regulates regenerative medicine

Korea governs advanced regenerative medicine through a dedicated statute — 첨단재생의료 및 첨단바이오의약품 안전 및 지원에 관한 법률, the Act on the Safety of and Support for Advanced Regenerative Medicine and Advanced Biological Products. The version currently in force is marked [시행 2026. 5. 12.] [법률 제21118호, 2025. 11. 11., 일부개정]. Its structure matters more than its detail for a patient: cell-based regenerative interventions run through designated institutions (재생의료기관) and through review of the proposed plan by a deliberation committee (재생의료 심의위원회), and are conducted either as clinical research or as treatment. The statute’s existence is not evidence that any particular clinic has passed those gates. That is a document a clinic either can or cannot show you.

The shape of the framework

The point worth internalising is that Korean law does not treat a cell-based regenerative intervention as something a clinic may simply decide to add to its menu. There are gates in front of it, and they are institutional rather than merely professional: the institution itself is designated, and the specific plan is reviewed.

Two further features are worth naming. The statute distinguishes regenerative medicine conducted as clinical research (재생의료 임상연구) from regenerative medicine conducted as treatment (재생의료 치료) — a distinction that determines what may be charged for and on what basis a patient is enrolled. And it runs alongside a separate track for advanced biological products (첨단바이오의약품), which are authorised as products rather than permitted as procedures. A material may therefore be lawfully manufactured without any given clinical use of it being authorised, and vice versa.

What the framework does not establish

This section exists because the most common error in reading regulatory pages is a quiet upgrade from “this is regulated” to “this is therefore approved.” The statute establishes a framework. It does not establish, for any specific clinic:

• that the clinic holds designation as a 재생의료기관;
• that any plan of theirs has been reviewed or approved by the committee;
• that a given material they use is an authorised 첨단바이오의약품;
• that a proposed intervention falls within the scope of whatever they are designated for;
• that an intervention marketed for cosmetic purposes has been through any of this at all.

Each of those is a separate fact with a separate document behind it. A clinic that is operating within the framework can produce the relevant one; that is what designation and review produce. The questions to ask a clinic page turns this list into phrasing you can use.

Why Korea specifically attracts this question

Korea has a large aesthetic medicine sector and a long history in this particular field. A bioethics analysis published in 2017 examined how stem cell marketing developed in South Korea and the United States, describing both as home to significant industries selling cell-based interventions ahead of conclusive evidence, and tracing the social and regulatory conditions that permitted it^[1]. That history is part of why the current statutory framework exists, and part of why a careful reader should ask specific questions rather than rely on national reputation in either direction.

For readers travelling to Korea, the relevant literature is broader than Korean law. A critical review of international stem cell tourism found that clinics offering these therapies cluster in jurisdictions with lighter oversight, that documented complications include infection, rejection and tumorigenesis, and that clinics generally provide little pre-travel health information^[2]. Commentary in the clinical literature has argued that the response has to come jointly from regulators, professional societies and physicians rather than from any one of them^[3]. The safety and risks page covers the documented harms in more detail.

Reading this page correctly

This is a description of a statutory framework written for patients, by a dermatology practice, and it is not legal advice. Statutes are amended — the version cited here carries its own amendment history in its title line — and their application to a specific set of facts is a question for a lawyer or the relevant authority, not a clinic website. Where you need to know whether a specific intervention is lawful for you to receive, ask the provider for their documentation and, if the answer matters enough, verify it independently.

Written by the Stem Cell Seoul editorial team and medically reviewed by a Korean Board-Certified Dermatologist (AAD International Fellow · ASLMS member). Last reviewed 2026-08-30.